Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the...
- REDEMPLO is being launched in China by Sanofi - NMPA approval triggers $10 million milestone payment to be paid by Sanofi to Arrowhead subsidiary Visirna Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032...
- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide...
– REDEMPLO is the first and only Health Canada-approved siRNA medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS – People living with FCS have extremely...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company’s Board of Directors approved “inducement”...
- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-barrier - Study initiation...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 37th Annual Healthcare Conference...